122 related articles for article (PubMed ID: 14523791)
1. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow JH; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Greenslade D; Goetz A; Grem JL
Semin Oncol; 2003 Aug; 30(4 Suppl 15):20-5. PubMed ID: 14523791
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow J; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Schuler B; Greenslade D; Goetz A; Knight R; Thomas R; Monahan BP; Dahut W; Grem JL;
J Clin Oncol; 2003 Jul; 21(14):2664-72. PubMed ID: 12860942
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
Doroshow JH; Synold TW; Gandara D; Mani S; Remick SC; Mulkerin D; Hamilton A; Sharma S; Ramanathan RK; Lenz HJ; Graham M; Longmate J; Takimoto CH; Ivy P
Semin Oncol; 2003 Aug; 30(4 Suppl 15):14-9. PubMed ID: 14523790
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Synold TW; Takimoto CH; Doroshow JH; Gandara D; Mani S; Remick SC; Mulkerin DL; Hamilton A; Sharma S; Ramanathan RK; Lenz HJ; Graham M; Longmate J; Kaufman BM; Ivy P;
Clin Cancer Res; 2007 Jun; 13(12):3660-6. PubMed ID: 17575231
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Gibbons J; Egorin MJ; Ramanathan RK; Fu P; Mulkerin DL; Shibata S; Takimoto CH; Mani S; LoRusso PA; Grem JL; Pavlick A; Lenz HJ; Flick SM; Reynolds S; Lagattuta TF; Parise RA; Wang Y; Murgo AJ; Ivy SP; Remick SC;
J Clin Oncol; 2008 Feb; 26(4):570-6. PubMed ID: 18235116
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Leal TB; Remick SC; Takimoto CH; Ramanathan RK; Davies A; Egorin MJ; Hamilton A; LoRusso PA; Shibata S; Lenz HJ; Mier J; Sarantopoulos J; Mani S; Wright JJ; Ivy SP; Neuwirth R; von Moltke L; Venkatakrishnan K; Mulkerin D
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1439-47. PubMed ID: 21479634
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
Gietema JA; de Vries EG; Sleijfer DT; Willemse PH; Guchelaar HJ; Uges DR; Aulenbacher P; Voegeli R; Mulder NH
Br J Cancer; 1993 Feb; 67(2):396-401. PubMed ID: 8431374
[TBL] [Abstract][Full Text] [Related]
11. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
O'Reilly S; Rowinsky EK; Slichenmyer W; Donehower RC; Forastiere AA; Ettinger DS; Chen TL; Sartorius S; Grochow LB
J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
18. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Fizazi K; Ducreux M; Ruffié P; Bonnay M; Daniel C; Soria JC; Hill C; Fandi A; Poterre M; Smith M; Armand JP
J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
[TBL] [Abstract][Full Text] [Related]
19. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
